Hypertension and COVID-19: Potential use of beta-blockers and a call for Randomized Evidence

• Main Authors: Mochamad Yusuf Alsagaff, -, Eka Prasetya Budi Mulia, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: Cardiological Society of India 2021
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/125540/1/1.%20Hypertension%20and%20COVID-19%20Potential%20use%20of%20beta-blockers%20and%20a%20call%20for%20evidenc_IHJ%202021.pdf; https://repository.unair.ac.id/125540/2/karil%201.pdf; https://repository.unair.ac.id/125540/3/1.%20Korespondensi.pdf; https://repository.unair.ac.id/125540/4/1.%20Turnitin.pdf; https://repository.unair.ac.id/125540/; https://www.sciencedirect.com/science/article/pii/S0019483221002303?via%3Dihub; https://doi.org/10.1016/j.ihj.2021.10.011
• Institution: Universitas Airlangga

Hypertension is one of the most common morbidities in COVID-19. Previous studies demonstrated that hypertension increases composite poor outcomes in patients with COVID-19. Beta-blockers is widely used as one of the most common antihypertensive agents. Beta-blockers may hold potential benefits in CO...